CAPN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL932019	0.80	14/20
SCHEMBL931203	0.68	13/20
SCHEMBL930920	0.60	13/20
SCHEMBL930579	1.00	12/20
SCHEMBL931241	0.85	12/20
SCHEMBL930942	0.82	12/20
SCHEMBL930321	0.80	12/20
SCHEMBL930997	0.80	12/20
SCHEMBL931593	0.57	12/20
SCHEMBL931289	0.54	12/20
SCHEMBL930000	0.54	12/20
SCHEMBL930611	1.00	11/20
SCHEMBL931644	1.00	11/20
SCHEMBL931991	0.77	11/20
SCHEMBL931525	0.63	11/20
SCHEMBL931065	0.58	11/20
SCHEMBL2217259	0.53	10/20
SCHEMBL2217110	0.52	10/20
SCHEMBL2217113	0.52	10/20
SCHEMBL2217115	0.52	10/20

Clinical trials — most relevant to CAPN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Minocycline for the Treatment of Early-Phase Schizophrenia	PHASE3	COMPLETED
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy	PHASE2/PHASE3	COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.	PHASE1/PHASE2	RECRUITING
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients	PHASE2	UNKNOWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy	EARLY_PHASE1	RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies	nan	UNKNOWN
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
LGMD R1 Natural History Study	nan	ACTIVE_NOT_RECRUITING
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study	nan	RECRUITING
Congenital Muscle Disease Study of Patient and Family Reported Medical Information	nan	RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts	nan	ACTIVE_NOT_RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China	nan	ENROLLING_BY_INVITATION
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS	nan	UNKNOWN
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program	nan	COMPLETED
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests	nan	UNKNOWN
Brain Involvement in Dystrophinopathies Part 2	nan	COMPLETED
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)	nan	COMPLETED
Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development	nan	COMPLETED
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
Genetics of Familial and Sporadic ALS	nan	COMPLETED
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CAPN2 binder may also engage these)

Protein	Name	Similarity
Q9GLG1	—	1.000	Q9GLG1 →
Q07009	—	1.000	Q07009 →
O08529	—	1.000	O08529 →
Q27971	—	1.000	Q27971 →
Q92178	—	1.000	Q92178 →
P00789	—	1.000	P00789 →
Q9GLG2	—	1.000	Q9GLG2 →
CAPN9	Calpain-9	1.000	landscape →
P97571	—	1.000	P97571 →
Q5NVS7	—	0.999	Q5NVS7 →
Q91VA3	—	0.999	Q91VA3 →
CAPN1	Calpain-1 catalytic subunit	0.999	landscape →
O35350	—	0.999	O35350 →
P35750	—	0.999	P35750 →
Q27970	—	0.999	Q27970 →
A6NHC0	—	0.998	A6NHC0 →
Q9TTH8	—	0.998	Q9TTH8 →
P20807	—	0.997	P20807 →
Q6J756	—	0.997	Q6J756 →
Q9D805	—	0.997	Q9D805 →
Q64691	—	0.996	Q64691 →
Q78EJ9	—	0.996	Q78EJ9 →
P06814	—	0.996	P06814 →
Q11002	—	0.995	Q11002 →
P16259	—	0.995	P16259 →
Q9GLG7	—	0.995	Q9GLG7 →
P43368	—	0.995	P43368 →
O35920	—	0.995	O35920 →
Q92177	—	0.994	Q92177 →
P43367	—	0.994	P43367 →